SAGE Sage Therapeutics
- 14.280
- +0.590+4.31%
Sage Therapeutics News
Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho
Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho
Sage Therapeutics Is Maintained at Neutral by Mizuho
Sage Therapeutics Is Maintained at Neutral by Mizuho
Express News | Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment
SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital
SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
Express News | Sage Therapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21
Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained
Sage Therapeutics (SAGE) has an average hold rating and price target range of $18 to $70, according to analysts polled by Capital IQ. Price: 13.73, Change: -0.27, Percent Change: -1.93
Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)
Needham Reiterates Hold on Sage Therapeutics
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Sage Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 — Needham Reiterates → Hold 04/18/2024 35.71% Scotiabank $34 → $19 Maintains Sector Outperform
SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals
SAGE Therapeutics, Inc. Q1 Loss Decreases, but Misses Estimates
Express News | Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time
Express News | Sage Therapeutics Inc - Anticipates Operating Expenses Will Decrease in 2024 Relative to 2023
Express News | Sage Therapeutics Inc - Does Not Anticipate Receipt of Any Additional Milestone Payments From Collaborations in Remainder of 2024
Express News | Sage Therapeutics Inc - Net Loss Was $108.5 Mln for Q1 of 2024 Compared to $146.8 Mln for Same Period in 2023
Analysis
Price Target
No Data
